Lupin Limited is a pharmaceutical company headquartered in Mumbai, India. The company was founded in 1968 and has operations in over 100 countries. Lupin is primarily engaged in the development, manufacture, and marketing of generic and branded pharmaceuticals, biosimilars, and specialty pharmaceuticals.
The company has a diversified portfolio of products across therapeutic areas such as cardiovascular, diabetes, respiratory, central nervous system, gastroenterology, and women’s health. Lupin has a strong focus on research and development, with significant investments in developing innovative products and drug delivery technologies. In terms of earnings, Revenue from Operations for Q3 FY23 was ₹4,244.56 crore, a 4% increase from ₹4,087.48 crore in the same period last year. The third quarter’s other income, which contributed ₹77.66 Crore to the Total Revenue. Meanwhile, the Profit Before Tax improved to ₹246.14 Crore from ₹167 Crore from the same quarter previous year. The Consolidated Net Profit was ₹157.65 crore, significantly down from ₹549 crore in the same quarter last year. This quarter’s earnings per share was ₹3.36.